Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Pulmonary Hypertension

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 157 articles:
HTML format



Single Articles


    March 2024
  1. NAEIJE R
    High altitude travelling with pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2400111.
    PubMed    


  2. HOWARD LS, Price LC
    Systematic pulmonary embolism follow-up: why we should all do it!
    Eur Respir J. 2024;63:2400253.
    PubMed    


    February 2024
  3. MULLER J, Titz A, Schneider SR, Bauer M, et al
    The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled cross-over trial.
    Eur Respir J. 2024 Feb 29:2301001. doi: 10.1183/13993003.01001-2023.
    PubMed     Abstract available


  4. GERGES C, Montani D, Humbert M, Lang IM, et al
    Hemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.
    Eur Respir J. 2024 Feb 15:2302280. doi: 10.1183/13993003.02280-2023.
    PubMed    


  5. DURRINGTON C, Hurdman JA, Elliot CA, Maclean R, et al
    Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry.
    Eur Respir J. 2024 Feb 1:2300846. doi: 10.1183/13993003.00846-2023.
    PubMed     Abstract available


    January 2024
  6. PLUNKETT MJ, Sayegh ALC, McWilliams TJ, Sithamparanathan S, et al
    The skeletal muscle metaboreflex: a novel driver of ventilation, dyspnoea and pulmonary haemodynamics during exercise in pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2300952.
    PubMed     Abstract available


    December 2023
  7. TAMURA Y, Tamura Y, Shigeta A, Hosokawa K, et al
    Adult-onset idiopathic peripheral pulmonary artery stenosis.
    Eur Respir J. 2023;62:2300763.
    PubMed     Abstract available


    November 2023
  8. HUMBERT M
    Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2301726.
    PubMed    


  9. NEPTUNE ER, Cardoso WV
    Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance.
    Eur Respir J. 2023;62:2301691.
    PubMed    


  10. PAUSCH C, Pittrow D, Hoeper MM, Huscher D, et al
    Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
    Eur Respir J. 2023;62:2301023.
    PubMed     Abstract available


    October 2023
  11. HADZIC S, Wu CY, Gredic M, Pak O, et al
    Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
    Eur Respir J. 2023 Oct 26:2201606. doi: 10.1183/13993003.01606-2022.
    PubMed     Abstract available


  12. WISSMULLER M, Wartner V, Hohmann C, Adler J, et al
    Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic: A Prospective, Randomised Cross-over Study.
    Eur Respir J. 2023 Oct 12:2201454. doi: 10.1183/13993003.01454-2022.
    PubMed    


  13. JEVNIKAR M, Solinas S, Brenot P, Lechartier B, et al
    Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension (CTEPH) with mixed anatomical lesions: a proof of concept.
    Eur Respir J. 2023 Oct 6:2300517. doi: 10.1183/13993003.00517-2023.
    PubMed    


  14. MCNEILL JN, Roshandelpoor A, Alotaibi M, Choudhary A, et al
    The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension.
    Eur Respir J. 2023;62:2300561.
    PubMed     Abstract available


  15. ANDRUSKA AM, Zamanian RT
    Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics.
    Eur Respir J. 2023;62:2301547.
    PubMed    


    September 2023
  16. HAFNER F, Kindt A, Strobl K, Forster K, et al
    MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
    Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
    PubMed     Abstract available


  17. PRICE LC, McCabe C, Weatherald J
    Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.
    Eur Respir J. 2023;62:2301513.
    PubMed    


  18. SOUZA R, Badesch DB, Ghofrani HA, Gibbs JSR, et al
    Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Eur Respir J. 2023;62:2301107.
    PubMed     Abstract available


    August 2023
  19. OLSSON KM, Fuge J, Park DH, Kamp JC, et al
    Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2301070.
    PubMed    


  20. ALABED S, Garg P, Alandejani F, Dwivedi K, et al
    Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2202225.
    PubMed     Abstract available


    July 2023
  21. PICCARI L, Blanco I, Torralba Y, Arismendi E, et al
    Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
    Eur Respir J. 2023 Jul 6:2300463. doi: 10.1183/13993003.00463-2023.
    PubMed    


  22. YEH FC, Chen CN, Xie CY, Baxan N, et al
    TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2300204.
    PubMed     Abstract available


  23. PAN HM, McClelland RL, Moutchia J, Appleby DH, et al
    Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2300190.
    PubMed     Abstract available


    June 2023
  24. LUIJTEN D, Talerico R, Barco S, Cannegieter SC, et al
    Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis.
    Eur Respir J. 2023 Jun 15:2300449. doi: 10.1183/13993003.00449-2023.
    PubMed    


  25. GONCHAROVA EA, Kudryashova TV, Pullamsetti SS
    Too hot? Too cold? Wnt signalling in pulmonary arterial hypertension: can we treat it "just right"?
    Eur Respir J. 2023;61:2300504.
    PubMed    


  26. CHAKRABORTY A, Nathan A, Orcholski M, Agarwal S, et al
    Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2201625.
    PubMed     Abstract available


  27. COTTIN V, Valenzuela C, Humbert M
    Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud.
    Eur Respir J. 2023;61:2300944.
    PubMed    


  28. WAXMAN A, Restrepo-Jaramillo R, Thenappan T, Engel P, et al
    Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Eur Respir J. 2023;61:2202414.
    PubMed     Abstract available


    May 2023
  29. DE MAN FS, Vonk Noordegraaf A
    The right ventricle tamed.
    Eur Respir J. 2023;61:2300509.
    PubMed    


  30. SAMARANAYAKE CB, Kempny A, Naeije R, Gatzoulis M, et al
    Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2300144.
    PubMed     Abstract available


    April 2023
  31. DE JONG CMM, Visser C, Bemelmans RHH, Boersma WG, et al
    Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism.
    Eur Respir J. 2023;61:2300171.
    PubMed    


  32. SCHMIDT KH, Milger K, Pausch C, Huscher D, et al
    Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis.
    Eur Respir J. 2023;61:2202440.
    PubMed     Abstract available


    March 2023
  33. KOUDSTAAL T, Boomars KA
    Inflammatory biomarkers in pulmonary arterial hypertension: ready for clinical implementation?
    Eur Respir J. 2023;61:2300018.
    PubMed    


  34. BOUCLY A, Tu L, Guignabert C, Rhodes C, et al
    Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2201232.
    PubMed     Abstract available


    February 2023
  35. EICHSTAEDT CA, Belge C, Chung WK, Graf S, et al
    Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.
    Eur Respir J. 2023;61:2201471.
    PubMed     Abstract available


    January 2023
  36. RUBIN LJ, Naeije R
    Sotatercept for pulmonary arterial hypertension: something old and something new.
    Eur Respir J. 2023;61:2201972.
    PubMed    


  37. PRICE LC, Weatherald J
    The new 2022 pulmonary hypertension guidelines: some small steps and some giant leaps forward for evidence-based care.
    Eur Respir J. 2023;61:2202150.
    PubMed    


  38. HUMBERT M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, et al
    Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Eur Respir J. 2023;61:2201347.
    PubMed     Abstract available


    December 2022
  39. GALKIN A, Sitapara R, Clemons B, Garcia E, et al
    Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
    Eur Respir J. 2022;60:2102356.
    PubMed     Abstract available


  40. ORMISTON ML, Jankov RP, Stewart DJ
    Oh NO! Loss of PHD2 leads to "radical" changes in the lung vasculature.
    Eur Respir J. 2022;60:2201776.
    PubMed    


    November 2022
  41. SHU T, Zhang J, Zhou Y, Chen Z, et al
    Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA.
    Eur Respir J. 2022 Nov 24:2200582. doi: 10.1183/13993003.00582-2022.
    PubMed     Abstract available


    October 2022
  42. MICKAEL C, Lee MH, Graham BB
    The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned.
    Eur Respir J. 2022;60.
    PubMed    


  43. BADAGLIACCA R, Papa S, D'Alto M, Ghio S, et al
    The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?
    Eur Respir J. 2022;60.
    PubMed     Abstract available


  44. ADNOT S, Lipskaia L, Bischof O
    What is hidden behind a pulmonary hypertensive, fibrotic and inflammatory phenotype?
    Eur Respir J. 2022;60.
    PubMed    


    September 2022
  45. RIOU M, Canuet M, Ghigna MR, Eyries M, et al
    First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01197-2022.
    PubMed    


  46. HASSAN HJ, Naranjo M, Kazzi B, Housten-Harris T, et al
    Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index.
    Eur Respir J. 2022;60.
    PubMed    


  47. DOUSCHAN P, Tello K, Rieth AJ, Wiedenroth CB, et al
    Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism.
    Eur Respir J. 2022;60.
    PubMed    


    August 2022
  48. HUMBERT M, Kovacs G, Hoeper MM, Badagliacca R, et al
    2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
    Eur Respir J. 2022 Aug 25. pii: 13993003.00879-2022.
    PubMed    


  49. VAN DE VEERDONK MC, Vonk-Noordegraaf A, Vachiery JL
    Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography.
    Eur Respir J. 2022;60.
    PubMed    


  50. LECHARTIER B, Girerd B, Eyries M, Beurnier A, et al
    Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers.
    Eur Respir J. 2022;60.
    PubMed    


  51. RAI N, Sydykov A, Kojonazarov B, Wilhelm J, et al
    Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.
    Eur Respir J. 2022;60.
    PubMed     Abstract available


    July 2022
  52. MADOUN S, Piliero N, Guillien A, Salvat M, et al
    Improved ventilatory efficiency to evidence haemodynamic improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2022 Jul 27. pii: 13993003.00762-2022.
    PubMed    


  53. LIU B, Peng Y, Yi D, Machireddy N, et al
    Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension.
    Eur Respir J. 2022 Jul 7. pii: 13993003.02643-2021.
    PubMed     Abstract available


  54. STUBBS H, Lua S, Brewis M, Johnson M, et al
    COMPERA 2.0 risk stratification in medically-managed chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2022 Jul 7. pii: 13993003.00313-2022.
    PubMed    


  55. GHOFRANI HA
    Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
    Eur Respir J. 2022;60.
    PubMed    


  56. DU M, Jiang H, Liu H, Zhao X, et al
    Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes.
    Eur Respir J. 2022;60.
    PubMed     Abstract available


  57. HOEPER MM, Pausch C, Olsson KM, Huscher D, et al
    COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Eur Respir J. 2022;60.
    PubMed     Abstract available


  58. SWINNEN K, Bijnens E, Casas L, Nawrot TS, et al
    Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium.
    Eur Respir J. 2022;60.
    PubMed    


    June 2022
  59. CERTAIN MC, Baron A, Turpin M, Ebstein N, et al
    Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units.
    Eur Respir J. 2022 Jun 9. pii: 13993003.00107-2022.
    PubMed    


  60. ALI MK, Schimmel K, Zhao L, Chen CK, et al
    The role of circular RNAs in pulmonary hypertension.
    Eur Respir J. 2022 Jun 9. pii: 13993003.00012-2022.
    PubMed     Abstract available


  61. BOUCLY A, Humbert M, Sitbon O
    To be or not to be... treated with initial combination therapy, that is the (PAH) question.
    Eur Respir J. 2022;59.
    PubMed    


  62. HOEPER MM, Pausch C, Grunig E, Staehler G, et al
    Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


  63. ZELT JGE, Sugarman J, Weatherald J, Partridge ACR, et al
    Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


  64. VAN DER HAVE O, Westoo C, Ahrne F, Tian X, et al
    Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT.
    Eur Respir J. 2022;59.
    PubMed    


  65. NAEIJE R, Richter MJ, Rubin LJ
    The physiological basis of pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


  66. WESSELS JN, Mouratoglou SA, van Wezenbeek J, Handoko ML, et al
    Right atrial function is associated with right venticular diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


  67. JUTANT EM, Tu L, Thuillet R, Picard V, et al
    Erythrocytes are altered in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed    


    May 2022
  68. NEDER JA, Phillips DB, O'Donnell DE, Dempsey JA, et al
    Excess ventilation and exertional dyspnoea in heart failure and pulmonary hypertension.
    Eur Respir J. 2022 May 26. pii: 13993003.00144-2022.
    PubMed     Abstract available


  69. AZZO L, Ali YS, Vaqar S, Dauriat G, et al
    Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort.
    Eur Respir J. 2022 May 20. pii: 13993003.02897-2021.
    PubMed     Abstract available


  70. BENATTIA A, Bugnet E, Walter-Petrich A, de Margerie-Mellon C, et al
    Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    March 2022
  71. TOSHNER M, Church C, Harbaum L, Rhodes C, et al
    Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available


    February 2022
  72. OLSSON KM, Richter MJ, Kamp JC, Gall H, et al
    Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation.
    Eur Respir J. 2022 Feb 10. pii: 13993003.03087-2021.
    PubMed    


    January 2022
  73. D'ALTO M, Di Maio M, Romeo E, Argiento P, et al
    Echocardiographic probability of pulmonary hypertension: a validation study.
    Eur Respir J. 2022 Jan 7. pii: 13993003.02548-2021.
    PubMed     Abstract available


    December 2021
  74. LAMMI MR, Samant S, Tran HV, Uddo RB, et al
    Jugular venous ultrasound predicts outcomes in pulmonary hypertension outpatients.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02591-2021.
    PubMed    



  75. "Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats." R. Dumitrascu, C. Kulcke, M. Konigshoff, et al. Eur Respir J 2011; 37: 1104-1118.
    Eur Respir J. 2021;58.
    PubMed    


  76. KHOURI C, Hlavaty A, Roustit M, Cracowski JL, et al
    Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database.
    Eur Respir J. 2021;58.
    PubMed    


  77. BRAAMS NJ, Boon GJAM, de Man FS, van Es J, et al
    Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    November 2021
  78. OGO T, Shimokawahara H, Kinoshita H, Sakao S, et al
    Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2021 Nov 25. pii: 13993003.01694-2021.
    PubMed     Abstract available


  79. BOUCLY A, Weatherald J, Savale L, de Groote P, et al
    External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry.
    Eur Respir J. 2021 Nov 4. pii: 13993003.02419-2021.
    PubMed     Abstract available


  80. GAZENGEL P, Hascoet S, Amsallem M, Savale L, et al
    Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension.
    Eur Respir J. 2021 Nov 4. pii: 13993003.02388-2021.
    PubMed    


  81. KOTSIMBOS T, Kaye D, Keating D
    Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!
    Eur Respir J. 2021;58.
    PubMed    


  82. LE RIBEUZ H, To L, Ghigna MR, Martin C, et al
    Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    October 2021
  83. CALLEJO M, Blanco I, Barbera JA, Perez-Vizcaino F, et al
    Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed    


  84. VALENTIN S, Maurac A, Sitbon O, Beurnier A, et al
    Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


  85. PETERS EL, Bogaard HJ, Vonk Noordegraaf A, de Man FS, et al
    Neurohormonal modulation in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    September 2021
  86. GREDIC M, Wu CY, Hadzic S, Pak O, et al
    Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.
    Eur Respir J. 2021 Sep 2. pii: 13993003.01153-2021.
    PubMed     Abstract available


  87. SAVALE L, Vuillard C, Pichon J, Boucly A, et al
    Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure.
    Eur Respir J. 2021;58.
    PubMed    


  88. WU Y, Wharton J, Walters R, Vasilaki E, et al
    The pathophysiological role of novel pulmonary arterial hypertension gene SOX17.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


  89. EVANS CE, Cober ND, Dai Z, Stewart DJ, et al
    Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    August 2021
  90. OLSSON KM, Hoeper MM, Pausch C, Grunig E, et al
    Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.
    Eur Respir J. 2021 Aug 12. pii: 13993003.01483-2021.
    PubMed    


  91. KIELY DG, Condliffe R
    Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow.
    Eur Respir J. 2021;58.
    PubMed    


  92. DECLERCQ M, Treps L, Bousfia S, Carmeliet P, et al
    Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed    


  93. SAVALE L, Akagi S, Tu L, Cumont A, et al
    Serum and pulmonary uric acid in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    July 2021
  94. MORRELL NW
    Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?
    Eur Respir J. 2021;58.
    PubMed    


  95. MONTANI D, Girerd B, Jais X, Laveneziana P, et al
    Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
    Eur Respir J. 2021;58.
    PubMed     Abstract available


    June 2021
  96. ABMAN SH, Mullen MP, Sleeper LA, Austin ED, et al
    Characterisation of Pediatric Pulmonary Hypertensive Vascular Disease from the PPHNet Registry.
    Eur Respir J. 2021 Jun 17. pii: 13993003.03337-2020.
    PubMed     Abstract available


  97. LAUNAY D, Sanges S, Sobanski V
    Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension.
    Eur Respir J. 2021;57.
    PubMed    


  98. PEREZ-OLIVARES C, Segura de la Cal T, Flox-Camacho A, Nuche J, et al
    The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease.
    Eur Respir J. 2021;57.
    PubMed    


  99. BAUER Y, de Bernard S, Hickey P, Ballard K, et al
    Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    May 2021
  100. STEWART S, Chan YK, Playford D, Strange GA, et al
    Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography.
    Eur Respir J. 2021 May 28. pii: 13993003.00832-2021.
    PubMed     Abstract available


  101. AWADA C, Grobs Y, Wu WH, Habbout K, et al
    R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models.
    Eur Respir J. 2021;57.
    PubMed    


  102. RAHAGHI FN, Hilton JF, Correa RA, Loureiro C, et al
    Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension.
    Eur Respir J. 2021;57.
    PubMed    


    April 2021
  103. OLDHAM WM, Hess E, Waldo SW, Humbert M, et al
    Integrating hemodynamics identifies an extreme pulmonary hypertension phenotype.
    Eur Respir J. 2021 Apr 8. pii: 13993003.04625-2020.
    PubMed    


  104. LLUCIA-VALLDEPERAS A, van Wezenbeek J, Goumans MJ, de Man FS, et al
    The battle of new biomarkers for right heart failure in pulmonary hypertension: is the queen of hearts NT-proBNP defeated at last?
    Eur Respir J. 2021;57.
    PubMed    


  105. AMSALLEM M, Sweatt AJ, Arthur Ataam J, Guihaire J, et al
    Targeted proteomics of right heart adaptation to pulmonary arterial hypertension.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    March 2021
  106. MACIAS D, Moore S, Crosby A, Southwood M, et al
    Targeting HIF2alpha-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    February 2021
  107. ULRICH S, Grunig E
    The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment.
    Eur Respir J. 2021;57.
    PubMed    


  108. BORGESE M, Badesch D, Bull T, Chakinala M, et al
    EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  109. LEWIS RA, Armstrong I, Bergbaum C, Brewis MJ, et al
    EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    January 2021
  110. SWINNEN K, Bijnens E, Casas L, Nawrot TS, et al
    Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy.
    Eur Respir J. 2021 Jan 21. pii: 13993003.02680-2020.
    PubMed    


  111. REMY-JARDIN M, Ryerson CJ, Schiebler ML, Leung ANC, et al
    Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


  112. BOGAARD HJ, Sitbon O
    Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated.
    Eur Respir J. 2021;57.
    PubMed    


  113. HAARMAN MG, Levy M, Roofthooft MTR, Douwes JM, et al
    Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension.
    Eur Respir J. 2021;57.
    PubMed     Abstract available


    December 2020
  114. DELCROIX M, Torbicki A, Gopalan D, Sitbon O, et al
    ERS Statement on Chronic Thromboembolic Pulmonary Hypertension.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02828-2020.
    PubMed     Abstract available


    November 2020
  115. KERANOV S, Dorr O, Jafari L, Troidl C, et al
    CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension.
    Eur Respir J. 2020 Nov 12. pii: 13993003.01192-2019.
    PubMed     Abstract available


  116. CONDLIFFE R, Kiely DG, Lewis RA
    Mild parenchymal lung disease is still lung disease.
    Eur Respir J. 2020;56.
    PubMed    


  117. GODINAS L, Harari S, Barbera JA, Montani D, et al
    Mild parenchymal lung disease is still lung disease.
    Eur Respir J. 2020;56.
    PubMed    


  118. RHODES CJ
    The cancer hypothesis of pulmonary arterial hypertension: are polyamines the new Warburg?
    Eur Respir J. 2020;56.
    PubMed    


    October 2020
  119. CAMBOULIVE A, Jutant EM, Savale L, Jais X, et al
    Reversible pulmonary hypertension associated with multivisceral Whipple's disease.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03132-2020.
    PubMed    


  120. SWIETLIK EM, Ghataorhe P, Zalewska KI, Wharton J, et al
    Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2020 Oct 15. pii: 13993003.03201-2020.
    PubMed     Abstract available


    September 2020
  121. BADAGLIACCA R, Vizza CD
    Imaging risk in pulmonary arterial hypertension.
    Eur Respir J. 2020;56.
    PubMed    


    August 2020
  122. GUIGNABERT C, Humbert M
    Targeting Transforming Growth Factor Beta Receptors in Pulmonary Hypertension.
    Eur Respir J. 2020 Aug 13. pii: 13993003.02341-2020.
    PubMed     Abstract available


  123. ADIR Y, Humbert M, Chaouat A
    Sleep-related breathing disorders and pulmonary hypertension.
    Eur Respir J. 2020 Aug 3. pii: 13993003.02258-2020.
    PubMed     Abstract available


  124. SOFIANOPOULOU E, Church C, Coghlan G, Howard L, et al
    Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
    Eur Respir J. 2020;56.
    PubMed    


    July 2020
  125. JEVNIKAR M, Montani D, Savale L, Seferian A, et al
    Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems.
    Eur Respir J. 2020 Jul 16. pii: 13993003.02208-2020.
    PubMed    


  126. MARON BA, Humbert M
    Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.
    Eur Respir J. 2020;56.
    PubMed    


    June 2020
  127. NEWNHAM M, Bunclark K, Abraham N, Ali S, et al
    CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension (CTEPH).
    Eur Respir J. 2020 Jun 8. pii: 13993003.02096-2019.
    PubMed     Abstract available


  128. BEHR J, Hoeper MM
    Subtle signs - red flags.
    Eur Respir J. 2020;55.
    PubMed    


    May 2020
  129. OLSSON KM, Fuge J, Brod T, Kamp JC, et al
    Oral iron supplementation with ferric maltol in patients with pulmonary hypertension.
    Eur Respir J. 2020 May 22. pii: 13993003.00616-2020.
    PubMed    


  130. DODSON MW, Sumner K, Carlsen J, Cirulis MM, et al
    The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2020 May 22. pii: 13993003.00774-2020.
    PubMed    


  131. LICHTBLAU M, Saxer S, Furian M, Mayer L, et al
    Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m.
    Eur Respir J. 2020 May 19. pii: 13993003.02474-2019.
    PubMed     Abstract available


  132. SITBON O, Reis A, Humbert M, Vonk Noordegraaf A, et al
    Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration.
    Eur Respir J. 2020;55.
    PubMed    


  133. VIS D, Boucly A, Humbert M, Weatherald J, et al
    Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
    Eur Respir J. 2020;55.
    PubMed    


  134. AUSTIN ED, Elliott CG
    TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form.
    Eur Respir J. 2020;55.
    PubMed    


  135. JANSEN SMA, van den Heuvel L, Meijboom LJ, Alsters SIM, et al
    Correspondence regarding "T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease": a single-centre case series.
    Eur Respir J. 2020;55.
    PubMed    


  136. THORE P, Girerd B, Jais X, Savale L, et al
    Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


  137. GHIO S, Crimi G, Guida S, Valentini A, et al
    Magnetic resonance imaging of pulmonary arterial compliance after pulmonary endarterectomy.
    Eur Respir J. 2020;55.
    PubMed    


    April 2020
  138. YOGESWARAN A, Richter MJ, Sommer N, Ghofrani HA, et al
    Evaluation of pulmonary hypertension by right heart catheterisation - does timing matter?
    Eur Respir J. 2020 Apr 29. pii: 13993003.01892-2019.
    PubMed    


  139. KIKUCHI H, Goda A, Takeuchi K, Inami T, et al
    Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty.
    Eur Respir J. 2020 Apr 20. pii: 13993003.01982-2019.
    PubMed     Abstract available


  140. DUAN D, Gu C, Jun JC
    Altered metabolism in pulmonary hypertension: fuelling the fire or just smoke?
    Eur Respir J. 2020;55.
    PubMed    


  141. TOSHNER M, Rothman A
    IL-6 in pulmonary hypertension: why novel is not always best.
    Eur Respir J. 2020;55.
    PubMed    


  142. BOTROS L, Vonk Noordegraaf A, Aman J
    Vanishing vessels aboding pulmonary disease: a role for VEGFR2.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  143. KLOK FA, Couturaud F, Delcroix M, Humbert M, et al
    Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.
    Eur Respir J. 2020 Mar 17. pii: 13993003.00189-2020.
    PubMed     Abstract available


  144. SHLOBIN OA, Kouranos V, Barnett SD, Alhamad EH, et al
    Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry.
    Eur Respir J. 2020 Mar 5. pii: 13993003.01747-2019.
    PubMed     Abstract available


  145. FRUMP AL, Lahm T
    Tips for success in pulmonary hypertension treatment: progress in isolating endothelial cells from pulmonary artery catheters.
    Eur Respir J. 2020;55.
    PubMed    


    February 2020
  146. PABST S, Grohe C, Skowasch D
    Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies.
    Eur Respir J. 2020;55.
    PubMed    


    January 2020

  147. "Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease." Laurent Savale, Anoosha Habibi, Francois Lionnet, Bernard Maitre, Vincent Cottin, Xavier Jais, Ari Chaouat, Elise Artaud-Macari, Matthieu Canuet, Gregoir
    Eur Respir J. 2020;55.
    PubMed    


    December 2019
  148. BOUVARD C, Genet N, Phan C, Rode B, et al
    Connexin 43 Is a Promising Target for Pulmonary Hypertension due To Hypoxemic Lung Disease.
    Eur Respir J. 2019 Dec 20. pii: 13993003.00169-2019.
    PubMed     Abstract available


  149. WAYPA GB, Schumacker PT
    Roles of HIF1 and HIF2 in pulmonary hypertension: it all depends on the context.
    Eur Respir J. 2019;54.
    PubMed    


    November 2019
  150. BOUCLY A, Morelot-Panzini C, Garcia G, Weatherald J, et al
    Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension.
    Eur Respir J. 2019 Nov 26. pii: 13993003.02108-2018.
    PubMed     Abstract available


  151. GRUNIG E, Benjamin N, Eichstaedt CA, Peacock AJ, et al
    Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension.
    Eur Respir J. 2019;54.
    PubMed    


    October 2019
  152. LEVY M, Moshous D, Szezepanski I, Galmiche L, et al
    Pulmonary hypertension after bone marrow transplantation in children.
    Eur Respir J. 2019 Oct 24. pii: 13993003.00612-2019.
    PubMed     Abstract available



  153. "Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?" Irene M. Lang and Hiromi Matsubara. Eur Respir J 2019; 53: 1900843.
    Eur Respir J. 2019;54.
    PubMed    


  154. LANG IM, Matsubara H
    Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?
    Eur Respir J. 2019;54.
    PubMed    


  155. JAIS X, Brenot P, Montani D, Fadel E, et al
    A roadmap for management of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2019;54.
    PubMed    


    March 2019
  156. ROSENZWEIG EB, Abman SH, Berger RMF
    Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns.
    Eur Respir J. 2019;53.
    PubMed    


  157. CALCATERRA G, Fanos V, Bassareo PP
    Still puzzling about a clear definition of pulmonary arterial hypertension in newborns.
    Eur Respir J. 2019;53.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.